Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Ascendis Pharma ADR (ASND)

Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders Newswire.ca - Wed Aug 23, 2023

/CNW/ - Ascendant Resources Inc. (TSX: ASND) (OTCQB: ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's 2023...

ASND : 140.89 (-0.90%)
ASND.TO : 0.0600 (unch)
Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders PR Newswire - Wed Aug 23, 2023

/PRNewswire/ - Ascendant Resources Inc. (TSX: ASND) (OTCQB: ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's...

ASND.TO : 0.0600 (unch)
ASND : 140.89 (-0.90%)
Why Shares of Ascendis Pharma Are Climbing Monday Motley Fool - Mon May 1, 2023

A critical response letter from the FDA means hope remains for the company's hyperthyroidism therapy candidate.

ASND : 140.89 (-0.90%)
ASCENDIS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ascendis To Contact Him Directly To Discuss Their Options PR Newswire - Sat Apr 22, 2023

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ascendis Pharma ("Ascendis" or the...

ASND : 140.89 (-0.90%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ascendis Pharma A/S - ASND PR Newswire - Wed Apr 19, 2023

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ascendis Pharma A/S ("Ascendis" or the "Company") (NASDAQ: ASND). Such...

ASND : 140.89 (-0.90%)
ROSEN, A TOP RANKED LAW FIRM, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation - ASND PR Newswire - Sun Apr 16, 2023

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of...

ASND : 140.89 (-0.90%)
Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock? Zacks - Wed Apr 12, 2023

Ascendis Pharma A/S (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more...

ASND : 140.89 (-0.90%)
AMRN : 0.8718 (-4.94%)
ASND EQUITY NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation - ASND PR Newswire - Mon Apr 10, 2023

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of...

ASND : 140.89 (-0.90%)
ASCENDIS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ascendis To Contact Him Directly To Discuss Their Options PR Newswire - Sat Apr 8, 2023

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ascendis Pharma ("Ascendis" or the...

ASND : 140.89 (-0.90%)
ASCENDIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ascendis Pharma A/S on Behalf of Ascendis Stockholders and Encourages Investors to Contact the Firm Business Wire - Fri Apr 7, 2023

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Ascendis Pharma A/S (“Ascendis” or the “Company”) (NASDAQ: ASND) on behalf...

ASND : 140.89 (-0.90%)

Barchart Exclusives

3 Energy Dividend Stocks Leading the S&P 500 Higher Barchart - Thu Apr 18, 6:30PM CDT
These three energy dividend stocks have outperformed the S&P 500 on a year-to-date basis, and rank among the index's top 20 performers of 2024 so far. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot